Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03964493 · ClinicalTrials.gov registry record · Phase 2
TNP-2092 to Treat Acute Bacterial Skin and Skin Structure Infection
A Phase 2 study, sponsored by TenNor Therapeutics Limited.
- Completed
- Registry status
- Phase 2
- Development phase
- 120
- Enrollment target
NCT03964493: Completed Phase 2 study, sponsored by TenNor Therapeutics Limited.
NCT03964493 is a Phase 2 study that has completed, run by TenNor Therapeutics Limited. The registered enrollment target is 120 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (10% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03964493, a Phase 2 study, has completed, sponsored by TenNor Therapeutics Limited.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 120 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate safety, tolerability, pharmacokinetic characteristics and efficacy of TNP-2092 in adults with ABSSSI suspected or confirmed to be caused by gram-positive pathogens.
Primary Outcome
Early clinical response is defined as responder meeting two criteria: (1) patient had at least a 20% reduction of acute bacterial skin and skin structure infection (ABSSSI) primary lesion size compared to baseline measurements; (2) patient did not die of any cause within 72 hours of the first dose of study treatment. An indeterminate classification is used for a response that could not be adequately inferred because study data are unavailable for evaluation of efficacy for any reason (eg, missin
Interventions
- DRUG Vancomycin
- DRUG TNP-2092
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2019-04-20 |
| Est. Completion | 2020-09-28 |
| Phase | Phase 2 |
What the finished NCT03964493 record still lists
NCT03964493 is an interventional study that assigns participants to a tested intervention. The registered 120 participants enrollment target is mid-sized for trials with a published cap, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (10% lower).
The record links to 0 conditions, and to 2 interventions - of which Vancomycin is the first listed.
NCT03964493 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03964493 about?
NCT03964493 is a clinical study titled "TNP-2092 to Treat Acute Bacterial Skin and Skin Structure Infection". The purpose of this study is to evaluate safety, tolerability, pharmacokinetic characteristics and efficacy of TNP-2092 in adults with ABSSSI suspected or confirmed to be caused by gram-positive pathogens.
What is the current status of trial NCT03964493?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 120 participants. The study started on 2019-04-20. Estimated completion is 2020-09-28.
What interventions are being tested in trial NCT03964493?
The interventions under investigation include: Vancomycin (DRUG), TNP-2092 (DRUG).
Who is sponsoring clinical trial NCT03964493?
This trial is sponsored by TenNor Therapeutics Limited, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03964493's enrollment target sits among peer trials
120 569th of 2000 higher than 1,383 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01174108 · 120 participants · Phase 2
Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused With a Reduced Dose of Non-Mobilized Donor T-cells
- NCT01627301 · 120 participants · NA
Sympathetic Overactivity in Post-traumatic Stress Disorder
- NCT02025023 · 120 participants · Phase 3
Local 5-Fluorouracil Injection for the Treatment of Chalazia: A Prospective, Comparative Study
- NCT02128906 · 120 participants · Phase 2
Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC: ERCC1 Biomarker Enrichment and Interaction Design
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI